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This study demonstrates the synthesis and release of 
prolactin (PRL) from dermal fibroblasts (>98%) ill 
vitro, suggesting a potential local source of PRL in 
skin. PRL release was first detected in confluent 
cultures (0.25 X 106 plated cells) on or before day 18 
and increased to a maximal level of 2 ng172 h by day 
30. Medroxyprogesterone acetate and estradiol (E2) 
had no effect on PRL release, but prostaglandin E2 
(PGE2) reduced the time required for PRL induction 
to 6-9 days. The steroids and PGE2 together were 
synergistic, reaching maximal values of - 10 ng172 h 
after 2 or more weeks of treatment. Dibutyryl-cyclic 
AMP, a second messenger in prostaglandin signal 
transduction, was also synergistic with medroxypro-
gesterone acetate and E2, but induced significant 
PRL expression in the absence of the steroids (28 and 
12 ng172 h, respectively). The increase in PRL release 
was not a result of increased cell proliferation, be-
A necdotal evidence suggests that skin physiology and hair growth are affected by agents that modulate serum prolactin (PRL) levels and its bioactivity ;11 ·";"0 .(i .e., emotional stres~, bromocriptine, .. or. cyc~o­sponn A). The observatIon that bromocnptllle 111-
duces remission of psoriatic epidermal lesions (Weber et aI, 
198:J.a,b) further suggests that the source of PRL involved in skin 
physiology is the pituitary gland. Thus, Paus (1991), who recently 
reviewed tlus subject, proposed that PRJ.. acts as a neuromodula tor 
of skin epithelial ce ll proliferation and the skin immune system. 
There is some evidence, though, that PRL may be synthesized 
and released locally in the skin. A PRL-like substance was demon-
strated by immunocytochemistry in human sweat glands (Robert-
son ct aI, 1989; Walker cf ai, 1989), suggesting a potential local 
source of PIli synthesis. Unfortunately, because immunocyto-
chem istry is not a definitive technique for the localjzation of protein 
synthesis, it is unk nown whether the PRL-like substance was 
syn thesized by the g land or merely taken up by the gland ce lJs . On 
the other hand, lymphocytes, wluch are known to synthesize and 
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cause the PRL-secreting cultures had 32.2 ± 8.8% less 
DNA (N = 5 individuals, 95% confidence limit) than 
control cultures after 3 weeks of treatment with 
dibutyryl-cyclic AMP, medroxyprogesterone acetate, 
and E2. Dermal fibroblast PRL was immunologically 
and electrophoreticallY identical to decidual and pi-
tuitary PRLs, and Northern blot analysis demon-
strated a PRL mRNA size of 1.15 kb. Maximal PRL 
release from fibroblast cells was 32.0 ± 6.1 ng/72 h 
(mean ± SD at 95% confidence limit) for a donor 
population representing both males (n = 15) and 
females (n = 7) between the ages of20-week gestation 
to 52 years. In contrast to term decidual fibroblast 
cells that also express PRL, dennal fibroblasts did not 
co-express insulin-like growth factor-binding pro-
tein-1. Key lVords: pyostaglt",dill Ezldibutyl'J'l-cyclic AMP! 
steroids!lVoll1ld-hea.lillg. ] Invest Derl1latol 106: 1250-1255, 
1996 
release PRL (Paner'li, 1993; R eber, 1993), migrate into skin 111 
response to trauma and actively participate in the regulation of 
wound-healing processes (Barbul, 1992). 
A thjrd, and potentially more abundant source of PRL ill skin, 
however, is the fibroblast cell. Fibroblast cells were first postulated 
as an extrapituit31'y source of PIli by Chapitis cf al (1989) who 
reported the spontaneous release of PR.L-Like immuno- and bio-
logical activity from ex plants of connective tissue (rectus facia). 
Although the specific cell-type responsible for PRL synthesis and 
release was not rigorously characterized, they postulated that 
fibroblast cells were the source of ti-lis PRL-like activity, because it 
was released from outgrowths of rapidly proliferating fusiform cells 
that were subpassaged and grown to conAuency. Progesterone and 
estradiol, wluch were known to induce PlU expression ill fibro-
blast-like endometrial stromal cells, had no effect on the release of 
the PRL-like activity from the connective tissue explants . Inlubi-
tion of its release by the cyclom:ygenase inhibitor ibuprofen, 
however, suggested the potential involvement of prostaglandins in 
the regulation of this prolactin-like substance. 
In a recent manuscript (Richards ct ai, 1995), we demonstrated 
that fibroblast cells of human term decidua synthesize and release 
PRL and insulin-like growth f.1ctor-binding protein-1 (IGFBP-1) 
when cultured in the presence of medroxyprogesterone acetate 
(MPA), estradiol (E2) , and prostaglandin E2 (PGE2) or its second 
messenger analogue, dibutyryl-cAMP (db-cAMP). Analogous to 
the release of PRL-Like material from connective tissue explants, 
MPA and E2 had no effect on the induction of PRL or IGFBP-l 
re lease iJ1 the absence of PGE2 or db-cA MP, but acted synergisti-
cally when given in combination with PGE2 or db-cAMP. In tlus 
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study , vve tested the hypothesis that PRL and IGFBP-l might be 
expressed by dermal fibroblast cells cultured in the presence of 
these agents. 
MATERJALS AND METHODS 
Isolation and Culture of Dermal Fibroblast Cells Dermal fibroblast 
cells isola ted by seq uential trypsin and coll agenase B digestion of forearm 
punch biopsies , or specimens from surgery or autopsy were obtained from 
the cytogeneti cs laboratory of C hildren's Hospital Medical Center (Cincin-
nati, OH) with Institutional R eview Board approva l. The dermal fibroblast 
cultures were released for this study afte r 1-3 passages, and maintained in 
RPM! 1640 medium (12.5 mM HEPES, 2% NaHCOJ , 25 U penicillin G per 
ml, 25 p,g streptomycin pe r ml , 5 ILg amphotericin- B per ml , pH 7.2) 
supplemented with 10% fe tal bovine serum (FBS) for at least two passages 
prior to b eing tested for PRL and IGFBP-l expression . 
Antibody Labeling and Flow Cytometry Cells (passage 3) were 
removed fro m the culture dish by treatment with 0.03'X, ethylenediammine 
letraacetic ac id in phosphate-buffered saline. 1 X 10" cells were th en washed 
with phosphate-buffered sa linc containing 0.2'Y" bovine serum albumin and 
0.01 % sodium azide. Non-specific binding sites were blocked by incubation 
with mouse IgG (Sigma C hemical Co. , St. Louis, M O) for 10 min at 4 C. 
The cell s were labe led with 20 ILl of flu orescein isothiocyanate (F1TC)-
conjugated mouse anti-human CD-45 (Parmingen, San Diego, CAl, FITC-
conj u gated mouse anti-human HLA-DR (Panningen), or F1TC-conjngated 
HLA- A,B ,C (Parmingen) for 30 min on icc . N onspecifi c antibody binding 
was monitored using FITC -conju gated mo use isotype IgG (Parmingen) . A 
total of 10,000 cell s w ere sorted for each antigen in a PACScan using LYSIS 
fI sofrvvare (Becton-Dickinson , San Jose, CAl. Freshly isolated human 
blood ITlononuclear cells were used as positive contro ls (not shown). 
Inununocytochemistry Vimentin, cytokeratin , Factor VIII , and sma-
actin were detected by immunocytochemical staining essenti ally as de-
scribed b y Wilfinger er al. (1984) . Passage 5 cells were plated at a density of 
lOO, OOO/well in a 24- well cul ture dish and allowed to attach overnight. The 
mediUlTI was then removed , and the cell s were rin sed with phosphate-
buffered saline and fixed w ith 3% gluteraldehyde in 0 .1 M N.oHPO" , pH 
7.2 . Monoclonal antibodies to cytokeratin (AEl / AE3 cocktail ; BioGenex 
Laboratories, San Ramon, CAl, vimentin (cat. 8143 18 ; Boehringer M ann-
heim, Indianapolis. IN). Factor VIII , and human sm a -actin (both fro m 
Cedarlane Labo ratories, H ornby, Ontario , Canada) were used at concen-
tratio n s reC0l111TICndcd by their respective luanufacturcrs and detec ted with 
a horseradish peroxidase-conjugated avidin-biotin anti-mouse IgG (Vec-
rastain E lite ABC Kit; Vector Laboratories, Burlingame, CA) . An upper 
limit for the propo rtion of positively stained cells w as estimated by counting 
positive- and negative-stained cells in a photograph of a single field at X I 00 
magnifica tio n (- 450 ce lls/ field) . 
Treatment Regimens Cells were plated at 0.25 X l OG/well in 24-well 
culture dishes with 11111 ofl0% F13S-supplemented RPMI 1640 medium (to 
measure PRL and IGFBP-l release) or at 1.0 X I O· / well in 6-well culture 
dishes with 4 1111 o f medium (for RNA isolation) and allowed to attach 
overnight before beginning treatment. Cells were then treated thro ughout 
the experim ent with FBS-supplemented medium alone (control medium). 
Ot FBS-supplel11ented medium containing: 1) 1 ILM MPA and 10 nM E2 ; 2) 
MPA and Eo in combinatio n with 50 f.LM db-cAMP; 3) MPA and E, in 
combination with 1 ILM PGE2 ; 4) db-cAMP alone; or 5) PGE2 alone. MPA, 
E, and PGE2 were dissolved in ethano l and added to the culture medium. 
The final concentratio n of alcohol never exceeded 0.09% (v/v). The 
mediunl was changed every third day and stored at -20C. 
Radiointmulloassay PRL was measured by ho mo logous radioimmuno-
assay (Sinha el aI, 1973) using material provided by the National H ormone 
and Pituitary Program, the Natio nal Institute of Diabetes and Digestive and 
Kidney Diseases. the N ational Institute of C hild Health and Human 
Development, and the U .S. Department of Agriculture. Each sample was 
assayed in dupli cate. The interassay variatio n (SEM at .EDso) was ::': 2% of 
the mean. 
Analysis ofmRNA Extractio n of tota l RNA using T ri Reagent (Molec-
ular Research Center, Inc., Cincinnati, OH) and Northern blot analysis of 
PRL and IGFBP-l ml~A was perfort11ed as previously describ ed (Richards 
et aI, 1995). 
Ligand Blot and Western Blot Analysis ofIGFBPs Proteins in 35 ILl 
of72-h- conditioned medium were analyzed by ligand blotting acco rding to 
the method of H ossenlo pp cr al (1987). Westem Blot analysis of IGFBP-l 
was performed o n th e same m embran e using rabbit anti-IGFDP-l (Upstate 
Biotechno logy Incorporated , Waltham, MA) . T he first an tibody was de-
tected b y chemiluminescence nsing horseradish peroxidase-conjugated don-
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Figure 1. Cells of a typical culture exhibited fusiform morphology 
and expressed vimentin, but little or no cytokeratin, Factor VIII, or 
sma-actin. The cells were plated at a density of 100,000 cells / well in a 
24-well culture dish and stained with hematoxylin-eosin stain (A) or probed 
for vimentin (B). cytokeratin (C), Factor VIII (D) , or sma-actin (E) by 
inll11unocytochenlistry. Purified 1110llSC IgG was used to assess no nspecifi c 
staining (F). Some nonspecific staining occurred when the cultures were 
p robed with mo noclonal antibody prepara tions against Pactor VIII and 
sm a-actin . The posi tively stained cells arc designated by -> (D,E). Scale IJar, 
200 ILm. 
key anti-rabbit IgG (Chemicon, Temecula, CAl in combination with the 
R enaissance detection system (Dupont-New England Nuclear; Boston, 
MA). 
Immunoextraction and Westenl Blot Analysis ofPRL Aliquots of a 
human pituitary extract and condi tioned m edia of dermal fibroblasts, term 
decidual fibroblasts, or term decidual tissue containing 250 ng of PIU (by 
radioimmunoassay) were made 1 mM phen ylmethylsulfonyl fluo ride, 5 mM 
ethylenediamine tetraacetic acid . 5 mM erhylelleglycol-bis(,B-amino-e thyl 
ether) N ,N'-tetra-ace tic acid , 0.01% thimerisol, and 0.02% NaN 3 in a final 
volume of 10 ml (RPM I 1640/ ]0% FBS) . PRL was immunoextracted 
overnight at roon1 tenlpcracurc \vith a polystyrene bead-conj ugated 1110no-
clonal antibody (Hybritech; San Diego, CAl . The bead w as then washed 
with phosphate-buffered saline (3 X 5 min). and the bound PRL was 
removed by brief incubatio n with 100 mM acetic acid (2 X 500 ILl , 5 min 
at room temperature) . The two acetic acid extracts were pooled , and the 
acetic add was renloved by vacuunl evaporation . T he proteins 'were 
resuspended in 60 ILl of reducing sample buffe r, and 45 ILl w as analyzed for 
PRL by W estern blo tting as described above, using a rabbit anti-PRL 
antibody (Chemicon International , Temecula , CAl. 
RESULTS 
Cell Cultures Consisted of >98% Fibroblast Cells The cells 
used in this study had a fusiform morphology and appeared 
essentially homogeneous by hematoJ.:ylin-eosin staining (Fig 1A). 
In a typical ce ll preparation, 100% of the cells expressed vimentin 
(Fig lB) , indicating cells of mesenchymal odgin. T his observation 
was consistent with the lack of cytokeratin expression (Fig 1 q , 
indica tive of epithelial cells. A minor fraction of the cells expressed 
Factor VIII (Fig lD) , an endothelial cell marker, Or sm a - actin (Fig 
lE), a m arker of myofibrobla sts and vascular smooth muscle cells. 
T he prevalence of such cells WaS < 1 % in each case, however. T he 
absence of CD-45, a m arker of aU nucleated bone marrow-derived 
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Figure 2. The isolated cells did not express bone marrow-derived 
cell surface antigens, CD-45 and HLA-DR, as determined by 
fluorescence flow cytornetry using FITC-conjugated monoclonal 
antibodies. The .... indicates endogcnous cellular fluorescence in the 
absence of FITC-conjugated mouse /gG. Detection of the cell surface 
antigen , HLA-A ,B,C, is included to d CI110 n stra tc a positi ve signal. 
cells including m acrophages, and the near absence of HLA-DR , a 
marker primari ly of macrophage cells, suggested little o r no 
contamination by bone marrow-derived cells (Fig 2) . From this 
analys is, it was estimated that > 98% of the cells were fibroblasts. 
Immunoreactive PRL Was Spontaneously Secreted, and Its 
Secretion Was Increased by Treatment with MPA, E 2 , and 
PGE2 or db-cAMP T he temporal re lease ofPRL from a typica l 
ceU culture exposed to several different treatment conditions is 
shown in Fig 3. At an initial p lating density of 0.2 5 X 10(' ce ll s per 
well (24-well plate, 2 cm 2 ) , PIli release was spontaneously in-
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Figure 3. PRL expression occurred spontaneously at high cell 
density and when treated for up to 30 days with various cODlbinatioDs 
ofMPA and E2 , db-cAMP, or PGE2 • Control mediulll (_); MPA + E2 (O); 
PGE, (+); PG~+MPA + E2 (.o); db-cAMP (~); and db-cAMP+MPA+~ 
(6 ). Passage 5 cells were plated 011 day - 1 at a cell density of 0.25 X 10· 
cells/ well in 24-wcll plates. Thc cells were thell cul tured ovcl11ight in concrol 
mcdiulll before starting trcaOllcnt. Valucs rcpresent the mean :!: SEM for PRL 
release in triplicate wells during 72-h culture intervals. 
duced on or before day 18. T he release of PIli tllen continued to 
increase through day 30, reaching a maxima] level of 2 ng/72 h. 
When the ce Li s were cultured in the presence of MPA and E2 , the 
tempora l pattern ofPRL expression was similar. In contrast, when 
cells were cultured with PGE2 or its second messenger analog, 
db-cAMP, PIli expression was first observed by treatment day 6 or 
9 and consistently reached maximal va lues at some po int between 
days 14 and 21. PGE2 had little o r no effect on the maximal level of 
PIli released , but db-cAMP increased the m aximal release of PIli 
by approximately 500"/., (12 ng/72 h for the experiment shown in 
Fig 3) . In contrast, a synerg isti c effect was observcd whcn dermal 
fibroblast ceUs were cultured with PGE2 or db-cAMP in combina-
tion with MPA and E2 . For the concentrations of db-cAMP and 
PGE2 used in these studies, the maximal release ofPRL in response 
to db-cA MP, MPA , and E2 consistently exceeded the max imal 
release of PIli from cells cultured with PGE2 , MilA, and ~ by 
100 - 200%. The average m aximal value of PIli re lease was 32.0 ± 
6. 1 ng/72 h when cells were cultured with db-cAMP, MPA, and 
E2 . This value represents the m eall ± SO at 95'% confidence limit 
(N = 22) for PIli released between days 18 and 21. The fibrobl asts 
were isolated from 22 individuals representing bo th sexes ranging 
in age from 20- week gestation to 52 yea rs. T he increase in PIli 
release was not a result of an increase in cell number because the 
treated cell cultures (db-cAMP, MPA, and E2) contained 32.2 ± 
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Figure 4. Dermal fibroblast PRL consisted primarily .of a monomer 
protein identical in size to PRL of pituitary a'.'d decldu.a. Il11l11uno-
extracted Pili fi'om term decidual fIbroblast-conditioned mcdlum (Ialle 1), 
dennal fi broblast-conditioned mcdium (Ialle 2). decidua] tissue-conciitioned 
medium (lillie J), and human pituitary extract (Ialle 4) was compared by 
Westen"! blot analysis. PIU in the conditioned medium of dermal fibrob lasts 
isolated from a second individual gave identi cal results (not shown) . 
8.8% less DNA than control cultures (mean ± SD of triplicate 
means from five individuals, 95% confidence limit) at the end of the 
nmecourse, when PRL release was maximal. 
mununoreactive PRL Was Biochemically Identical to De-
cidual and Pituitary PRLs Western blot analysis (Fig 4) 
indicated that the m;tior PRL species in conditioned medium of 
dermal fibroblast cells was MW 23,000 . This was also the major 
PRL species in pituitary extract, in conditioned medium of term 
decidual tissue, and in the conditioned medium of term decidual 
fibroblasts treated with db-cAMP, MPA, and E2. A second PRL 
species in dermal fibroblast-conditioned m~dium corresponded to 
the size of PRL dimer (MW 46,000), but bttle o r no glycosylated 
PRL (MW 25,000) was detected. 
Northern blot analysis indicated that the induction of PRL 
release in dermal fibrob lasts was accompanied by the induction of 
PRL rnRNA synthesis. As shown in Fig 5, PRL mRNA was not 
detectable in 10 !kg of total RNA isolated from dermal fibroblasts 
I on day 0 (1 day after plating), but after induct. ion ofPRL re lease by treatment with db-cAMP, MPA, and E2, 10 !kg of total RNA 
contained an easi ly detectable mRNA band of 1.15 kb that 
hybridized to a PRL cDNA probe. The PRL mRNA in de.rmal 
fi broblasts was the same size as PRL mRNA isolated from deCidual 
tissue. In contrast, pituitary PRL mRNA was smaller by approxi-
mately 150 bases. 
Dertnal Fibroblasts Did Not Co-express IGFBP-1 Figure 6 
shows the results of a Westem blot analysis of lGFBP-l in the 
conditioned medium of dermal fibroblasts treated with or without 
db-cAMP, MPA, and E2 for 18 days. For comparison, IGFBP-1 in 
rhe conditioned medium of term decidual fibroblast cells cultured 
under identica l conditions is also shown. No [GFBP-1 was released 
by dernlal or term decidual fibrob last cells cultured for 3 or 18 days 
in control medium, but the medium of term decidual fibroblasts 
treated for 18 days with db-cAMP, MPA, and E2 contained 
substantial quantities of IGFBP-1. In contrast, no LGFBP-l was 
detected in similarly treated dermal fibroblasts. The absence of 
IGFBP-1 in the conditioned m edium of dermal fibroblast cells was 
not the result of poor cell viability or slower metabolic rate because 
ligand blot analysis of the same membrane indicated that IGFBP-3 
and IGFBP-4 were secreted in similar amounts by both cell types 
(day 18+). In agreement with the Western blot data, mRNA for 
IGFBP-1 was not detected in 10 !kg of total RNA isolated from 
dermal fibrobl ast cells on day 0 or after 18 days of treatment with 
db-cAMP, MPA and E2 (Fig 5) . 
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Figure 5. The presence of PRL (Figs 3 and 4) and the absence of 
IGFBP-l (Fig 6) in dermal fibroblast-conditioned medium corre-
lated with an increase in the steady state level of 1.15-kb PRL 
mRNA and the lack of detectable IGFBP-l mRNA. Total RNA was 
extracted from dermal fibroblast cells on treatment day 0 (DF-O) or aftcr 24 
days oftrearment \\~th db-cAMP. MPA. and E, (DF.24) when PRL release 
had reached maximal values (see Fig 3). For both time points, 10 f.Lg of total 
RNA was compared by Northern blot analysis for PR.L and IGFBP- l 
mRNA content. Tota l RNA of human decidual tissue (D , 3 f.Lg) and human 
pituitary (1', 50 ng) were also ,,,,alyzcd for comparison. The same samples 
were run on two separate gels and probed with ['2P]cDNA specific for PRL 
or IGFBP-l. A second sample of RNA from decidual tissue was ana lyzed in 
the Northeru blot probed for PIU. 
DISCUSSION 
Although the role of pituitary PIli in the growth and development 
of the mammary glands is well-recognized, the discovery of 
extra pituitary sources of PRL suggests a much larger role for PRL 
in human physiology . Extrapituitary tissues that synthesize and 
release PRL include the decidualized uterine endometrium (Golan-
der et ai, 1978; Riddick et ai, 1978), the myometrium (Walters et ai, 
1983; Gellersen et ai, 1991), sweat g lands (Walker et ai, 1989; 
R obertson et ai, 1989), connective tissue (Chapitis c/ ai , 1989), the 
hypothalamus (Beyer et ai , 1992; Schachter et ai, 1984; Fields et ai , 
1993), thymocytes (O'Neal et ai, 1992), and lymphocytes (DiMattia 
ct ai, 1990; Pellegrini e; ai , 1992; Panerai, 1993; Reber, 1993). PRL 
mRNA has also been detected in mammary tissue as well as in 
breast, lung, endometrial, and m edullary thyroid carcinomas (Fields 
et ai, 1993). The function of PRL secreted fi:om these sources is 
poorly understood, but it is generally believed that PRL synthesized 
and secreted from extrapituitary sources acts locally, in a paracrine 
and/ or autocrine manner. 
This study demonstrates the synth esis and release of PRL from 
dermal fibroblast cells cultured ill Il itro. The m;tior PRL species 
detected in dermal fibroblast- conditioned medium was MW 23,000 
monomer PRL. PRL dimer (MW 46,000) was also present as a 
minor component, but little or no MW 25,000 glycosylated PRL 
(Lewis e/ ai, 1984, 19B9; Fonseca et ai , 1991) was detected. 
Immwlological identity to pituitary PRL was suggested by the fact 
that serial dilutions of dermal fibroblast-conditioned medium gave 
a linear response when assayed by radioimmunoassay using a 
polyclonal antibody for pituitary PRL (not shown). Immunological 
identity with decidual and pituitary PI lis was further indicated by 
the results of the Western blot shown in Fig 2. For this experiment, 
equal amounts of PRL (determilled by radioimmunoassay) from 
dermal fibroblast, decidual fibroblast, tenn decidua, and pituitary 
were subjected to immunoextraction followed by Western blot 
analysis with immunodetection . Because different antibodies (both 
polyclonal and monoclonal) were utili zed for each of the immu-
noaffinity inte ractions (radioimmunoassay, immunoextraction, and 
il11munodetection), the essentially equal intensities of MW 23 ,000 
PIli bands strongly suggest that dernlal fibroblast PRL is immu-
nologica lly identical to decidual and pituitary PRLs. T he size of the 
PRL mRNA in dermal fibroblasts was also found to be consistent 
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Figure 6. IGFBP-l was not present in dermal fibroblast-conditioned medium with or without db-cAMP, MPA, and E2 treatment. Duplicate 
samples were assayed by Western blot analysis after 3 and 18 days of culture in contro l medium or after 18 days oftrcatment with db-cAMP. MPA. and E2 • 
IGFBP-l leve ls in condi tioned medium of dermal fibroblasts did not increase over that of the contro l medium (A1). For comparison , the conditioned medium 
of term decid ual fi broblasts cultured under identical condjtions was also assayed . T he Ijgand blot of the same membrane indicates that both cell types secreted 
similar levels ofIGFBP-3 and IGFBP-4. 
with previously reported PRL mRNA sizes. As w ith other extra-
pituitary source.s of PIU in human tissues (DiMattia e/ ai, 1990; 
Gellersen et ai, 1991; O'Neal e/ ai, 1992), PRL mRNA in dermal 
fibroblasts was approximately 150 bases larger than pituitary PRL 
mRNA. T he larger PRL mRNA in humans is the product of an 
alternatively spliced RNA that incorporates an additional 5' non-
coding ex on (DiMattia et ai, 1990). T hese results indicate that 
induction of dernlal fibroblast PIU occurs at both the mRNA and 
protein levels, and that the expressed protein is authentic PIU. To 
date, 22 dern13l fibroblast ce ll cu ltures have been tested, and all of 
them expressed PRL. T he cells were isolated from both m ale (n = 
15) and female (n = 7) individuals flmging in age from 20-week 
gestation to 52 years, indicating that ill v itro expression of dermal 
fibrob last PRL is not dependent on the age or gender of the 
donating individu al. 
f ibroblasts are generally identified by their highly proliferative 
nature, their fusiform appearance, and their location in the mesen-
chymal stroma. With the current interest in mesenchym al-epithe-
lial ce ll interactions, however, it has become clear that fi broblasts 
are a highly diverse cell population that exhibit unique phenotypes 
(Schor et ai, 1994). Even within a single tissue, phenotypically 
distinct subpopulations of fibrob last ce ll s have been identified (Fries 
et ai, 1994; Germain et ai , 1994; Schmitt-Graff et ai, 1994; Schor e/ 
ai, 1994). In this study, we demonstrated that dermal fibroblast cells 
express PRL. Both the temporal expression and the magnitude of 
PRL re lease was similar to that of term decidual fibroblast cells 
cultured under the sam e conditions (Richards e/ ai, 1995). In 
contrast to term decidual fibroblasts, however, dermal fibrob lasts 
spontaneously expressed PRL at high cell density and did no t 
co-express the insu lin- like growth factor binding protein, IGFBP-1. 
T hus, in additio n to the basic properties that define fibroblast cells, 
the fib roblasts of skin and decidua share the potential to express 
PRL, but differ in their capacity to express IGFBP-1. T hese results 
and the results of Chapitis e/ al (1989) contradict the genera lly held 
belief that PRL expression is a unique property of the decidualized 
uterine endometl;al stroma, and suggest that PRL expression in the 
decidua is a specialized case of PRL expression in mesenchymal 
stroma, generally. 
Although the ro le of PRL in the decidua is unclear , our current 
understanding of the context ofPRL expression in the decidua m ay 
provide som e insight toward understanding the potential role of 
PRL in skin . PIU is expressed in the uterine endometrial stroma as 
a result of the differentiation of fibrob last-like stromal cells to a 
PRL-producing cell. This process of differentiation , or decidualiza-
tion, has been likened to an acute inflammatory response, primarily 
beca use of the infiltration of bone-marrow derived cells, the 
secretio n of inflammatory cytokines, and the ti ssue remodelling that 
occurs (Cross e/ ai, 1994) . If PRL expression occurs under these 
conditions in the endometrium, one might expect that PIU expres-
sion in skin would occur in response to inflammation and may be 
involved in wound-healing processes. In our experim ents, a low 
level of PRL expression occurred spontaneously in confluent 
cultures of dermal fibrobl ast cells, sugges ting that PIU expression 
il/. villo might be induced by autocrine stimulation. Such a mccha-
lusm could be involved in wound healing, w here rapid proliferation 
of fi broblast cells is required for the reconstruction of tissue 
scaffolding and initia l wound closure. Because keratinocytes expres 
PRL receptors (Girolomoni et ai, 1993; O uhtit et ai, 1993; Nagano 
and Kelly, 1994) and proliferate in response to PRL ill I/i/,.o 
(Girolomoni e/ ai , 1993), they are potential target cells for the 
action of fibroblast prolactin . T hus, it may be that the cell 
density-dependent autocrin e regulation of PRL in fi broblast ce lls 
provides a temporal signal for the induction of keratinocyte prolif-
era tion required for reconstruction of the epidermis. Similarly, a 
de fect in the regulation of fibroblast PRL might lead to skin 
pathologies, like psoriasis, which are characterized by aberrant 
regulation of keratinocyte proliferation and differentiation. 
The expression ofPRL by dermal fibroblasts ill llilro suggests that 
PRL is synth esized and secreted in the skin . Although the skin and 
decidua are very di.fferent tissues, the similar regulation of PRL 
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expression in dermal and term decidual fibroblast cells suggests that 
fundan"len tal insights may be gained by comparative studies ofPRL 
expression in th ese tissues. 
T/Ie authors IIIallk A lIlIClle Siall/bllllgll of Ill e Clli/dre,,'s H O;l'ila/ CylogCllelics 
IAboratOlJ' Jar Ill e fibro/i/asl cell w/tllres IIsed ill Illis swdy. J¥e arc II/SO grattfll/ for 
tile lech.,.,ica/ assistOllce of Dr. Hiroaki Jikillara (flOIl' cyllmre/r)') alld Ill e IId!!fll/ 
SIIggestiol1S of Drs. Edilll Mark~ff; SWarl Halldlllcrger, A llOop K. Brar, OIld Gracll le 
R. Fral1k. S "pporled, ill p0l1, by Naliolla/fllslillll"S of Hea /III Grnlll H D-15201. 
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